Veerendra Munugalavadla Acerta Pharma, AstraZeneca Group Biography Publications Institution JoVE Articles Veerendra Munugalavadla has not added a biography. If you are Veerendra Munugalavadla and would like to personalize this page please email our Author Liaison for assistance. Publications A Randomized Phase 2 Trial of Pembrolizumab Versus Pembrolizumab and Acalabrutinib in Patients with Platinum-resistant Metastatic Urothelial Cancer Cancer. Oct, 2020 | Pubmed ID: 32757302 Acalabrutinib with or Without Obinutuzumab Versus Chlorambucil and Obinutuzmab for Treatment-naive Chronic Lymphocytic Leukaemia (ELEVATE TN): a Randomised, Controlled, Phase 3 Trial Lancet (London, England). 04, 2020 | Pubmed ID: 32305093 Acalabrutinib Plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia Cancer Discovery. 03, 2020 | Pubmed ID: 31915195 إعداد الكريات الخلايا أحادية النووية الدم المحيطي والبلازما من سحب الدم واحد في مواقع التجارب السريرية لتحليل العلامات الحيوية Paola Marco-Casanova1, Natalia Lukashchuk1, Benedetta Lombardi1, Veerendra Munugalavadla2, Melanie M. Frigault3, Elizabeth A. Harrington1, J. Carl Barrett3, Andrew J. Pierce1 1Translational Medicine, R&D Oncology, AstraZeneca, 2Acerta Pharma, AstraZeneca Group, 3Translational Medicine, R&D Oncology, AstraZeneca JoVE 60776 Medicine
إعداد الكريات الخلايا أحادية النووية الدم المحيطي والبلازما من سحب الدم واحد في مواقع التجارب السريرية لتحليل العلامات الحيوية Paola Marco-Casanova1, Natalia Lukashchuk1, Benedetta Lombardi1, Veerendra Munugalavadla2, Melanie M. Frigault3, Elizabeth A. Harrington1, J. Carl Barrett3, Andrew J. Pierce1 1Translational Medicine, R&D Oncology, AstraZeneca, 2Acerta Pharma, AstraZeneca Group, 3Translational Medicine, R&D Oncology, AstraZeneca JoVE 60776 Medicine
